Carbohydrate digestive enzyme inhibition, hepatoprotective, antioxidant and antidiabetic benefits of Persea americana.

The medicinal use of Persea americana in the treatment of some diseases like hypertension, diabetes, is often with dearth of supporting scientific proof. Thus, we evaluated its ethnomedicinal benefits for possible scientific justification. Thirty healthy Wistar rats were randomly grouped in fives. Alloxan was used to induce diabetes in the rats in groups II to VI. The diabetic rats in group II were treated with glibenclamide, while those in group III were not treated. Also, the diabetic rats in groups IV to VI were treated with the ethanol extracts of the stem bark, leaf, and root of P. americana respectively. The parts of P. americana comparatively possess highest amounts of phenols (250.50 ± 0.68-bark), saponin (436.80 ± 3.76-leaf), flavonoid (382.80 ± 0.67-leaf) and tannins (58.34 ± 0.09-root). The extracts exhibited high reducing property (FRAP and total reducing), as well as high ABTS and DPPH free radical scavenging ability. The enzyme (alpha-glycosidase and alpha-amylase) inhibitory activity of P. americana increases with increasing concentration of the extracts. Administration of methanol extracts of P. americana bark, leaf and root to alloxan-induced diabetic rats resulted in significant (P < 0.05) decreases in AST, ALP, ALT, Total bilirubin, LPO, plasma glucose and significant (P < 0.05) increases in GSH, CAT and SOD. These effects were like that of glibenclamide. The enzyme inhibitory, hepatoprotective, antioxidant and antidiabetic properties of P. americana are some of the benefits derived from its consumption and ethnomedicinal use.

Synclisia scabrida protects against oxidative stress, hepatotoxicity and hyperglycaemia in alloxan-induced diabetic rats.

Background: Synclisia scabrida is commonly used in traditional medical practices for the management of diseases like diabetes and its complications. This study seeks to establish a scientific rationale for this practice. Methods: Thirty Wistar rats were randomly and equally grouped into six. Alloxan was used to induce diabetes in the rats in groups 2 to 6. The diabetic rats in group 2 were treated with glibenclamide, while those in group 3 were not treated. Also, the diabetic rats in groups 4, 5 and 6 were, respectively, treated with the ethanol extracts of the stem, root and leaf of S. scabrida. After 28 days of treatment, blood and organ samples were collected for biochemical studies. Results: S. scabrida possesses high amounts of useful phytochemicals. It also exhibits high total reducing capacity, FRAP activity, DPPH and ABTS scavenging ability. The inhibition of the α-glucosidase and α-amylase activities by the methanol extracts of S. scabrida stem, leaf and root were significantly (p < 0.05) higher than that of glibenclamide. Administration of S. scabrida extracts to the alloxan-induced diabetic rats caused significant (p < 0.05) decreases in the blood glucose, total bilirubin, AST, ALT, and ALP of the treated groups as compared to that of the untreated group. Treatment with the extracts also resulted in significantly (p < 0.05) lower LPO and significantly (p < 0.05) higher levels of GSH, SOD and CAT. Conclusion: S. scabrida extracts exhibited antioxidative, hepatoprotective and hypoglycaemic properties which are similar to that of the standard drug, glibenclamide.